Periotrap pharmaceuticals Headquarters & Office Locations

Periotrap pharmaceuticals (Private) is headquartered in Halle (Saale), Saxony-Anhalt, Germany. Founded in 2018, the company operates across 1 countries with approximately 9 employees worldwide.

Where is Periotrap pharmaceuticals's main office?

Periotrap pharmaceuticals's main headquarters office is located at Weinbergweg, Halle (Saale), Saxony-Anhalt 06120. This serves as the company's primary corporate address and is home to its executive leadership team.

Periotrap pharmaceuticals regional offices

Beyond its headquarters in Halle (Saale), Periotrap pharmaceuticals maintains 2 offices across 1 countries. Regional offices span 1 countries.

Periotrap pharmaceuticals contact information

The main switchboard for Periotrap pharmaceuticals headquarters can be reached at —. For investor relations, visit periotrap.com/investor-relations.

What does Periotrap pharmaceuticals do?

PerioTrap develops an innovative anti-infective drug for the curative treatment of periodontitis, an inflammatory gum disease caused by specific bacteria. Although this is a common indication associated with a range of comorbidities currently concerning around 30% of the global population, there is no effective treatment on the market yet. Moreover, the most relevant therapy option to date is a painful procedure consisting of the manual removal of plaque within the dental pockets followed by cleansing using either antiseptic solutions or broad spectrum antibiotics. This however leads to various side effects. Besides the potential development of antimicrobial resistances, the current treatment also results in the destruction of the protective biofilm which usually functions as a natural protective layer. Therefore, PerioTrap develops locally applied small molecule drugs that address a new target, which is only present within the pathogenic bacteria, but will not affect commensals. Thus, pathogens within the biological flora of the dental pocket will be selectively removed without affecting the protective biofilm. Furthermore, a local long-term release of our formulation will maintain its physiological function by preventing a pathogenic recolonization of the dental pockets which typically causes the reoccurrence of periodontitis. Accordingly, PerioTrap aims to eradicate the root of the disease and to ultimately restore patient confidence.